Boehringer Mannheim Gmbh

Roche Diagnostics Gmbh

Hartmut Schetters

Christa Hubner-Parajsz

Helmut Lenz

Winfried Albert

Josef Endl

Klaus Erler

Thomas Meier

Rolf Deeg

Rosemarie Kientsch-Engel

Andreas Gallusser

Martin Kaufmann

The invention concerns monoclonal antibodies against a complex of human ACT and a serine protease, preferably against a ACT-PSA, which have essentially no cross-reactivity with free, non-complexed human ACT and with free, non-complexed PSA, as well as diagnostic test methods for detecting serine protease-ACT complexes, in particular PSA-ACT, using these monoclonal antibodies.

Monoclonal antibodies against a human act and serine protease complex

The present invention provides an immunological process for the determination of the luteinizing hormone (LH), wherein at least one monoclonal antibody is used which is directed against LH and cross-reacts with other glycoprotein hormones to an extent of less than 3%. The present invention also provides a reagent for the determination of the luteinizing hormone, wherein it contains at least one monoclonal antibody which is directed against LH and cross-reacts with other glycoprotein hormones to an extent of less than 3%. Furthermore, the present invention provides a monoclonal antibody against the luteinizing hormone and a process and a hybridoma cell line for producing it.

Process and reagent for the determination of the luteinizing hormone and

A process for quantification of cell populations or subpopulations, by incubating a sample with labelled antibodies directed against characteristic surface antigens of the cell population to be quantified to form labelled antibody/antigen complexes. Standards with known, differing particle concentration and having comparable sedimentation behaviour to the cells to be determined and further, carrying molecules which are directed against the labelled antibody or a part hereof are also incubated with the labelled antibodies. The cells of the sample solution, as well as the particles of the standard solution, are separated off from the excess labelled antibodies and the amount of the labelling is measured not only on the cells but also on the particles. By comparison of the measurement value from the sample with the measurement values from the standard solutions, there is ascertained the number of cells to be determined in the sample. The standard and a reagent kit for carrying out the process are also the subject of this application.

Process for the quantification of cell populations or subpopulations and

A process for quantification of cell populations or subpopulations, by incubating a sample with labelled antibodies directed against characteristic surface antigens of the cell population to be quantified to form labelled antibody/antigen complexes. Standards with known, differing particle concentration and having comparable sedimentation behavior to the cells to be determined and further, carrying molecules which are directed against the labelled antibody or a part hereof are also incubated with the labelled antibodies. The cells of the sample solution, as well as the particles of the standard solution, are separated off from the excess labelled antibodies and the amount of the labelling is measured not only on the cells but also on the particles. By comparison of the measurement value from the sample with the measurement values from the standard solutions, there is ascertained the number of cells to be determined in the sample. The standard and a reagent kit for carrying out the process are also the subject of this application.

The present invention provides an immunological process for the determination of the follicle-stimulating hormone (FSH), wherein there is used at least one monoclonal antibody which is directed specifically against FSH and cross-reacts with other glycoprotein hormones to an extent of less than 3%. The present invention also provides a reagent for the determination of the follicle-stimulating hormone, wherein it contains at least one monoclonal antibody which is directed against FSH and cross-reacts with other glycoprotein hormones to an extent of less than 3%. Furthermore, the present invention provides a monoclonal antibody against the follicle-stimulating hormone and a process and a hybridoma cell line for producing it.

Growing community of inventors

Penzberg, Germany

Hartmut Schetters